The company has introduced Ramiven in strengths of 50 mg, 100 mg, 150 mg and 200 mg, for treating early breast cancer (EBC).from Moneycontrol Business News https://ift.tt/aYkUl7F
Subscribe to:
Post Comments (Atom)
LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally
A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...
-
By BY BEN HUBBARD AND AURELIEN BREEDEN from NYT World https://ift.tt/3oyLkdW >
-
By STEPHANIE SAUL from NYT U.S. https://nyti.ms/2WdcYAk >
No comments:
Post a Comment